Targeted Oncologics Require Individualized Tumor Characterization – Amgen
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Tarceva’s Paucity Of EGFR Status Data Reflects “Emerging Problem” – FDA Review
A possible lack of survival benefit for Tarceva in epidermal growth factor receptor-negative patients led FDA to require postmarketing studies addressing receptor status, despite OSI’s insistence that EGFR status is “not important,” review documents state.
AstraZeneca Could Seek New Indication For Iressa In Europe
AstraZeneca Iressa European Marketing Authorization Application withdrawn following the non-small cell lung cancer therapy’s failure to show a survival benefit in recent study. FDA is expected to provide an update on the status of gefitinib’s Subpart H approval in January or February
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: